NYSE:MYOVMyovant Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.48 +0.07 (+0.56 %) (As of 05/27/2020 04:00 PM ET) Add Compare Share Today's Range$11.59Now: $12.48▼$12.5550-Day Range$7.84MA: $11.58▼$13.3152-Week Range$4.14Now: $12.48▼$19.58Volume541,111 shsAverage Volume660,893 shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/ABeta2.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Myovant Sciences Ltd. has partnership with Flo Health to create a digital tool to screen for heavy menstrual bleeding. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMyovant Sciences has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Myovant Sciences has a potential upside of 92.3% from its current price of $12.48.Amount of Analyst CoverageMyovant Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesMyovant Sciences has received 199 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMyovant Sciences has received 185 “underperform” votes. (Add your “underperform” vote.)Community SentimentMyovant Sciences has received 51.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote “Outperform” if you believe MYOV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMyovant Sciences does not currently pay a dividend.Dividend GrowthMyovant Sciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myovant Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,976,151.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.68% of the stock of Myovant Sciences is held by insiders.Percentage Held by InstitutionsOnly 34.22% of the stock of Myovant Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myovant Sciences are expected to grow in the coming year, from ($2.96) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myovant Sciences is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myovant Sciences is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.93 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webmyovant.com Phone44-20-7400-3351Debt Debt-to-Equity Ratio5.88 Current Ratio1.02 Quick Ratio1.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.20) per share Price / Book-10.40Profitability EPS (Most Recent Fiscal Year)($3.37) Net Income$-288,990,000.00 Net MarginsN/A Return on Equity-2,288.94% Return on Assets-172.45%Miscellaneous Employees86 Outstanding Shares89,870,000Market Cap$1.12 billion Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable MYOV Rates by TradingView Receive MYOV News and Ratings via Email Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. Myovant Sciences (NYSE:MYOV) Frequently Asked Questions How has Myovant Sciences' stock been impacted by COVID-19 (Coronavirus)? Myovant Sciences' stock was trading at $8.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYOV shares have increased by 43.4% and is now trading at $12.48. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Myovant Sciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Myovant Sciences. When is Myovant Sciences' next earnings date? Myovant Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Myovant Sciences. How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd (NYSE:MYOV) released its quarterly earnings data on Monday, May, 18th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.77) by $0.04. View Myovant Sciences' earnings history. What price target have analysts set for MYOV? 5 equities research analysts have issued twelve-month target prices for Myovant Sciences' stock. Their forecasts range from $15.00 to $34.00. On average, they anticipate Myovant Sciences' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 92.3% from the stock's current price. View analysts' price targets for Myovant Sciences. Has Myovant Sciences been receiving favorable news coverage? News stories about MYOV stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myovant Sciences earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMyovant Sciences. Are investors shorting Myovant Sciences? Myovant Sciences saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,030,000 shares, an increase of 11.0% from the March 31st total of 2,730,000 shares. Based on an average daily trading volume, of 902,400 shares, the short-interest ratio is currently 3.4 days. Approximately 9.4% of the shares of the stock are short sold. View Myovant Sciences' Current Options Chain. Who are some of Myovant Sciences' key competitors? Some companies that are related to Myovant Sciences include Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Zai Lab (ZLAB), Evotec (EVTCY), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Allakos (ALLK), Biohaven Pharmaceutical (BHVN) and Arrowhead Pharmaceuticals (ARWR). View all competitors. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Energy Transfer LP Unit (ET), Amarin (AMRN), NVIDIA (NVDA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Carnival (CCL), Coty (COTY), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD) and Micron Technology (MU). Who are Myovant Sciences' key executives? Myovant Sciences' management team includes the following people: Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)Mr. Frank L. Karbe, Chief Financial Officer (Age 51)Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)Ms. Julie Tran MBA, MSHR, Sr. VP of HRMs. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51) When did Myovant Sciences IPO? (MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers. What is Myovant Sciences' stock symbol? Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." Who are Myovant Sciences' major shareholders? Myovant Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.25%), Wellington Management Group LLP (3.57%), Cormorant Asset Management LP (2.90%), Victory Capital Management Inc. (2.71%), Victory Capital Management Inc. (2.71%) and Lord Abbett & CO. LLC (2.11%). Company insiders that own Myovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Ferreira Juan Camilo Arjona, Frank Karbe, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang and Sciences Ltd Roivant. View institutional ownership trends for Myovant Sciences. Which institutional investors are selling Myovant Sciences stock? MYOV stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Wellington Management Group LLP, Victory Capital Management Inc., Victory Capital Management Inc., OneAscent Financial Services LLC, Raymond James & Associates, UBS Group AG, and Janus Henderson Group PLC. Company insiders that have sold Myovant Sciences company stock in the last year include Frank Karbe, Kim Sablich, and Matthew Lang. View insider buying and selling activity for Myovant Sciences. Which institutional investors are buying Myovant Sciences stock? MYOV stock was bought by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Morgan Stanley, Morgan Stanley, Ikarian Capital LLC, Two Sigma Investments LP, Connor Clark & Lunn Investment Management Ltd., Ghost Tree Capital LLC, and Deutsche Bank AG. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Frank Karbe, Kathleen Sebelius, Mark Altmeyer, and Sciences Ltd Roivant. View insider buying and selling activity for Myovant Sciences. How do I buy shares of Myovant Sciences? Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Myovant Sciences' stock price today? One share of MYOV stock can currently be purchased for approximately $12.48. How big of a company is Myovant Sciences? Myovant Sciences has a market capitalization of $1.12 billion. The company earns $-288,990,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe. What is Myovant Sciences' official website? The official website for Myovant Sciences is myovant.com. How can I contact Myovant Sciences? Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3351 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
